Business Wire

CA-RECOVER

Share
Recover™, Happy Punt and Hansae Form a Strategic Partnership to Achieve Circular Fashion for All

Three leading companies in the textiles industry, Recover™, Happy Punt, and Hansae, have entered into a multi-year partnership agreement to provide end-to-end solutions for the design, development, and production of sustainably conscious apparel for the fashion industry. The partnership allows retailers and brands to seamlessly integrate sustainable Recover™ recycled cotton fiber into their products, thereby helping to solve one of the world’s biggest environmental issues.

Using innovative technology, the partnership provides a range of services, including 3D design, patterns, tech packs, samples, and production to support brands and retailers at every step in the supply chain. The partnership offers a unique speed to market solution for the production of fully sustainable apparel and leverages the group’s global reach, with offices in Seoul, Barcelona, and New York. In addition, close customer proximity provides in-market technical design services that develop, review and approve all specifications to ensure correct fit and brand enhancing products.The partnership also provides an end-to-end service that combines the advantages of production nearshore and offshore worldwide.

Dedicated leading edge design and development facilities can produce samples in house from concept to finished sample with a quick turnaround time. Notably, as part of a joint sustainability initiative, the partnership also encourages R&D designs to be replaced by 3D designs to reduce the environmental impact of the sampling process.

The three leading companies have a combined experience of over 130 years in each of their respective fields. Each firm’s commitment to bringing the best technology to the product and the market offers a disruptive approach to the traditional apparel design and production process. The partnership is proud to be actively working with leading global brands to deliver sustainable collections to the market by Spring 2022, and more collections are expected to follow.

Recover™ will increase its production to 200,000 metric tons of recycled cotton fiber per year by 2025 to support the current market demand. This recycled cotton volume will save nearly three trillion liters of water each year, equivalent to the drinking water consumed by 3 billion people on an annual basis and allow 500,000 acres of land to be directed away from cotton cultivation to other uses.

The Recover™, Happy Punt, and Hansae strategic partnership provides brands and retailers with an easy plug & play solution to achieve their sustainability initiatives and ensures a quality product for the consumer.

About Recover™

Recover™ is a leading material sciences company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all.

As a fourth-generation, family-owned company with over a 70-year history in the textile industry, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets.

For more information, visit www.recovertex.com and follow @recoverfiber on social media.

About Happy Punt

Happy Punt is a design and manufacturing end-to-end solution provider to the fashion industry, applying virtual design tools supported by the best technology offering an efficient and sustainable product development and design process. Founded in 1996, Happy Punt has more than 25 years of history in the fashion business, and a team of 80 fashion designers and PD&D. Happy Punt offers a “Gold Standard” of excellence in technical and production know-how that ensures the manufacturing and delivery of safe and reliable products by providing a global end-to-end service recognized for the quality of their fashion design and for the speed of their creative process.

About Hansae

Established in 1982, Hansae Co., Ltd. has maintained consistent growth through specialized apparel exports and annually produces over 300 million garments. Hansae has 14 global corporations in 7 countries, over 600 people at the corporate Headquarters, and over 35,000 in the global manufacturing workforce.

Its mission is to enrich customer’s lives and lead fashion culture by providing the best quality clothes at a reasonable price. Quality management systems maximize values for its customers by ensuring manufacturing excellence and on-time, safe delivery of products.

Hansae has developed HAMS, its own smart factory system to maximize the efficiency of production plants in Vietnam, Indonesia, Myanmar, Nicaragua, Guatemala, and Haiti.

Hansae aims to be a front-runner in sustainable management by establishing ‘10% For Good’, pledging to donate 10 percent of its net profits from sustainable orders to third parties that work toward improving ocean environment by collecting wastes, the advancement of green raw materials, and hardware upgrades and retrofits.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 08:00:00 CET | Press release

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ®BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI® (eculizumab), OBODENCE® (denosumab), and XBRYK® (denosumab)Pre-filled syringe (PFS) presentation to become available in Europe in the second quarter of 2026 Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizuma

Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 15:00:00 CET | Press release

The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch

Aster Guardians Global Nursing Award 2026 Worth $250,000 Extends Deadline Till 11th January 202631.12.2025 14:08:00 CET | Press release

Due to an extraordinary global response of over 134,000 registrations from 214 countries, the submission deadline has been extended.Nurses worldwide can submit their nominations via www.asterguardians.com The Aster Guardians Global Nursing Award 2026, an initiative from Aster DM Healthcare – a leading integrated healthcare provider, has announced the extension of its deadline to January 11, 2026. The awards have already received over 134,000 registrations from 214 countries, highlighting its growing global reach and recognition among nurses worldwide. Nurses from around the world can submit their nominations through the dedicated platform at www.asterguardians.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231986766/en/ Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire) This year, the prestigious award will be hosted in New Delhi, India, celebrating nursing excellence on a truly global stage. T

Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation31.12.2025 11:59:00 CET | Press release

Tecnotree, a global digital platform and services provider for communications service providers (CSPs), today announced that it has been referenced as a Representative Provider alongside Google, Anthropic, Dropzone AI, DRUID, Palo Alto Networks, and Pegasystems in the Gartner® Innovation Insight: “AI SOC Agents Accelerate CSP SecOps Transformation,” published in December 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231210303/en/ Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation The Gartner Innovation Insight examines the emerging role of AI-driven Security Operations Centre (SOC) agents in CSP environments, outlining how these agents are used to automate and augment security operations across signalling, core networks, RAN, Open RAN, and roaming domains. The research discusses use cases such as alert triage, investigation support, thr

UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy30.12.2025 15:15:00 CET | Press release

The newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by SMA Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230695275/en/ World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospital in Dubai, UAE, along with parents, and the hospital team. (Photo: AETOSWire) SMA is a rare neuromuscular disorder that progressively weakens muscles responsible for movement and breathing. This newly licensed one-time therapy addresses the root genetic cause

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye